LifeScience Vaccines
Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International Pte. Ltd. will ...
January 20, 2022 | News
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,...
January 20, 2022 | News
Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing ...
January 18, 2022 | News
Shingrix is a non-live, recombinant subunit adjuvanted vaccine, given intramuscularly in two doses, for the prevention of shingles (herpes zoster). The vac...
January 10, 2022 | News
A team of researchers from A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering and Bioimaging (IBB), together with the Natio...
January 07, 2022 | News
Molnupiravir was earlier approved under Emergency Use Authorisation from CDSCO, India. This is the first oral antiviral approved by India, the UK agency an...
January 06, 2022 | News
Vaccines have been a trending topic ever since the coronavirus outbreak two years ago. DreamTec Research Limited (DreamTec, http://www.dreamtec.hk) ha...
January 05, 2022 | News
CT-P63 demonstrated a well- established safety profile in the global Phase I trial CT-P63 maintained strong neutralising ability against the Omicron var...
January 04, 2022 | News
A team of scientists led by Dr. Su-Jun Deng from biologics of Jemincare R&D Center, and another team of scientists from SIMM of CAS, led by P...
January 04, 2022 | News
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,...
December 29, 2021 | News
Japan’s Ministry of Health, Labor and Welfare Approves Molnupiravir for the Treatment of SARS-CoV-2 Infection Molnupiravir, First Oral COVID-19 Anti...
December 27, 2021 | News
The vaccine belongs to the latest fifth generation vaccine technology, targeting the S-RBD protein of the COVID-19 mutant strain, the trimer subunit vaccin...
December 27, 2021 | News
Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG...
December 23, 2021 | News
SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emergency Use Li...
December 22, 2021 | News
Most Read
Bio Jobs
News